Pharmafile Logo

News and Press Releases

New Real-World Data Published in Journal of Cardiac Failure on Effectiveness of VYNDAQEL (tafamidis) in Patients with Transthyretin Cardiac Amyloidosis

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. 6 August 2024 -- Walton Oaks, UK -- Pfizer Ltd today announced publication...

Category: Drug Discovery, Other, Pharmaceutical
Posted: August 8, 2024

Pfizer
235 East 42nd Street NY, NY 10017

CARBOGEN AMCIS Announces Two Successful FDA Inspections at its Manufacturing Sites in Neuland and Aarau, Switzerland

23 July 2024 -- Bubendorf, Switzerland -- Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of...

Category: BioManufacturing, Other, Pharmaceutical
Posted: July 23, 2024

CARBOGEN AMCIS
info@carbogen-amcis.com
Hauptstrasse 171 CH-4416 Bubendorf Switzerland

Certa Therapeutics Receives EU Orphan Designation for FT011, a GPR68 Inhibitor Being Developed as an Anti-Fibrotic Treatment for Systemic Sclerosis

22 July 2024 -- Melbourne, Australia -- Certa Therapeutics, a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the European Medicines Agency...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 22, 2024

Certa Therapeutics
info@certatherapeutics.com
Level 9, 31 Queen Street Melbourne VIC 3000 Australia

Evotec and Pfizer collaborate to advance drug discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases 11 July 2024, Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:...

Category: Drug Discovery
Posted: July 11, 2024

Just – Evotec Biologics
info@evotec.com
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumours in a Clinical Update Presented at ASCO 2024

An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 5, 2024

Corbus Pharmaceuticals Holdings
info@corbuspharma.com
500 River Ridge Drive Norwood, MA 02062

FDA and CluePoints Sign New 3 Year Cooperative Research and Development Agreement to Assess Data Quality using Statistical Modelling and Machine Learning

FDA extends its use of CluePoints to include AI/ML within an automated system to assess data quality in multicenter clinical trials 5 June 2024 -- Pennsylvania, US -- CluePoints, providers...

Category: Biotechnology, Pharmaceutical
Posted: June 5, 2024

CluePoints
contact@cluepoints.com
1000 Continental Drive, Suite 240, King of Prussia, PA 19406

Asymchem Secures Former Pfizer Sandwich, UK, Development and API Pilot Plant Manufacturing Facilities

21 May 2024 -- Teda Tianjin, P R China -- Asymchem Laboratories announced today that it will operate the former Pfizer UK small molecule API pilot plant and part of...

Category: BioManufacturing, Pharmaceutical
Posted: May 21, 2024

Asymchem
inquiry@asymchem.com
Asymchem Laboratories (Tianjin) Co., Ltd No. 6 Dongting 3rd Avenue, TEDA Tianjin, 300457, P.R. China

Headlands Research Announces Fifth Research Site under Partnership with Pfizer to Improve Diversity in Clinical Trials

Headlands Research Orlando satisfies the organisations’ commitment to create multiple research sites aimed at increasing health equity in clinical research 28 March 2024 -- California, US -- Headlands Research, a...

Category: Clinical Trials
Posted: April 2, 2024

Headlands Research
130 John F Kennedy Dr STE 203 Lake Worth, FL 33462

Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by US Food and Drug Administration

Compound is currently undergoing clinical trials as a potential treatment option for patients with RET altered tumours 5 March 2024 -- London, UK -- Ellipses Pharma, a global drug development...

Category: Drug Discovery
Posted: March 5, 2024

Ellipses Pharma
enquiries@ellipses.life
10 STRATTON STREET W1J 8LG LONDON

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

Six-year collaboration recognised at prestigious awards ceremony for its continued success in advancing OOC research to support widespread adoption across the pharmaceutical industry 23 November 2023 -- Cambridge, UK --...

Category: Clinical Trials
Posted: November 23, 2023

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ

Signum Surgical Completes Clinical Trial for BioHealx

Galway based company compiling data for submission of a De Novo classification request to US FDA Novel surgical option for the treatment of anal fistula, a painful and debilitating colorectal...

Category: Clinical Trials
Posted: September 12, 2023

Signum Surgical
INFO@SIGNUMSURGICAL.COM
NEW DOCKS, THE DOCKS, GALWAY